Department of Child Health, Women and Children's Hospital, School of Medicine, Xiamen University , Xiamen, China.
Department of Nephrology, Xiamen Haicang Hospital , Xiamen, China.
Expert Rev Respir Med. 2021 Feb;15(2):257-265. doi: 10.1080/17476348.2020.1822741. Epub 2020 Sep 17.
To understand the clinical effectiveness and safety of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19.
A retrospective cohort study was used to analyze the case data of 200 inpatients diagnosed with common-type COVID-19 at Wuhan Hospital. Participants were divided into a control group and an experimental group. The control group was treated with Arbidol hydrochloride capsules while the experimental group was treated with combination Arbidol hydrochloride capsules and Shufeng Jiedu Capsules (SFJDC) for 14 days.
Defervescence was achieved more rapidly in the experimental group ( < 0.05). The white blood cell count and the lymphocyte percentage in the experimental group were higher than that of the control group ( < 0.05). CRP and IL-6 levels in the experimental group were significantly lower than those in the control group ( < 0.05). The proportion of chest CT studies showing resolution of pneumonia in the experimental group was significantly higher than that in the control group ( < 0.05).
A treatment regimen of Shufeng Jiedu Capsules combined with Arbidol to treat common-type COVID-19, combining traditional Chinese and western allopathic medicine, improves time to recovery, has better clinical effectiveness, and is safe.
了解疏风解毒胶囊联合利巴韦林（阿比多尔）治疗普通型 COVID-19 的临床疗效及安全性。
采用回顾性队列研究，分析 200 例在武汉市某医院确诊为普通型 COVID-19 的住院患者的病例资料。将参与者分为对照组和实验组。对照组给予盐酸阿比多尔胶囊治疗，实验组给予盐酸阿比多尔胶囊联合疏风解毒胶囊（SFJDC）治疗，疗程均为 14 天。
实验组退热时间更快（ < 0.05）。实验组的白细胞计数和淋巴细胞百分比高于对照组（ < 0.05）。实验组的 CRP 和 IL-6 水平明显低于对照组（ < 0.05）。实验组肺部 CT 检查显示肺炎吸收的比例明显高于对照组（ < 0.05）。
疏风解毒胶囊联合利巴韦林治疗普通型 COVID-19 的方案，结合了中医和西医的优势，能缩短恢复时间，提高临床疗效，且安全可靠。
